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Fyn is a cytoplasmic tyrosine kinase (TK) which belongs to Src-family kinases (SFKs). 
These enzymes play a key role in many phases of cell life, such as differentiation, 
adhesion and survival. Fyn, analogously to other SFK members, is overexpressed in a 
number of solid and hematologic malignancies. Furthermore, several studies showed 
the involvement of Fyn in different central nervous system pathologies, such as 
Alzheimer’s and Parkinson’s diseases.[1] 
Our group recently performed an interdisciplinary work which, combining 
molecular modelling studies, synthesis and biological assays, led to the identification 
of two members of the in-house library of pyrazolo[3,4-d]pyrimidines as potent Fyn 
inhibitors. These compounds possess Ki values of 70 and 95 nM on Fyn, show 
antiproliferative activity on different cancer cell lines and are active in an in vitro 
Alzheimer’s model.
[2] 
On the basis of these interesting results, we decided to synthesize a new 
generation of compounds in order to extend structure-activity relationship (SAR) 
evaluation on this family of inhibitors. In particular, we introduced different 
decorations on C3 and C6 of the heterocyclic scaffold, while we maintained in N1 and 
C4 the features giving the best results in the first series of derivatives. Enzymatic 
assays are still in progress and on the basis of these results we will orient future 
biological assays and synthesis.  
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